focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biodyn Regulatory News (OBD)

Share Price Information for Oxford Biodyn (OBD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.80
Bid: 7.50
Ask: 7.98
Change: -0.10 (-1.28%)
Spread: 0.48 (6.40%)
Open: 8.40
High: 8.40
Low: 7.70
Prev. Close: 7.84
OBD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

9 Dec 2016 10:04

RNS Number : 4518R
Oxford BioDynamics PLC
09 December 2016
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Oxford BioDynamics plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

ODEY ASSET MANAGEMENT LLP

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

06 DECEMBER 2016

6. Date on which issuer notified:

08 DECEMBER 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

REACHES 10%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Share

(GB00BD5H8572)

0

0

8,609,823

8,609,823

10.00%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

8,609,823

10.00%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Odey European Inc. holds 4.28%. All other funds hold less than 3%.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

FERGUS LEE

15. Contact telephone number:

020 72081400

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEAEANEEAKFFF
Date   Source Headline
2nd Oct 20187:00 amRNSIssue of Equity
26th Sep 20187:00 amRNSIssue of Equity
18th Sep 20187:00 amRNSConsortium with OBD receives ?4m Horizon 2020 fund
4th Sep 201810:03 amRNSTotal Voting Rights
30th Aug 20182:57 pmRNSHolding(s) in Company
29th Aug 20184:52 pmRNSHolding(s) in Company
29th Aug 20184:48 pmRNSHolding(s) in Company
29th Aug 20184:47 pmRNSHolding(s) in Company
29th Aug 20184:46 pmRNSHolding(s) in Company
29th Aug 20184:43 pmRNSHolding(s) in Company
22nd Aug 20187:00 amRNSChinese Investment Group Takes Stake in OBD
19th Jul 20187:00 amRNSGrant of Canadian patent for EpiSwitch platform
17th Jul 20187:00 amRNSOBD presents latest EpiSwitch data at ASH Summit
2nd Jul 20185:50 pmRNSTotal Voting Rights
26th Jun 20187:00 amRNSALS study published in peer reviewed journal
19th Jun 20187:00 amRNSIssue of Equity
22nd May 20187:00 amRNSInterim Results for the Period Ended 31 March 2018
1st May 20187:00 amRNSTotal Voting Rights
17th Apr 20187:00 amRNSNotice of Interim Results
5th Apr 201811:41 amRNSIssue of Equity
28th Mar 20187:00 amRNSPublication in Journal of Translational Medicine
19th Mar 20187:00 amRNSPDMR Dealing/Grant of Share Options
16th Mar 20187:00 amRNSALS biomarker data presented at World CNS Summit
15th Mar 20182:10 pmRNSResults of Annual General Meeting
15th Feb 20187:00 amRNSPublication of Annual Report and Notice of AGM
14th Feb 20181:11 pmRNSGrant of Indian patent for EpiSwitch platform
30th Jan 20187:01 amRNSShore Capital appointed as NOMAD and Sole Broker
30th Jan 20187:00 amRNSFinal Results for the Year Ended 30 September 2017
29th Jan 20187:00 amRNSCollaboration in sports-related concussions
16th Jan 20187:00 amRNSNotice of Results
5th Jan 20183:05 pmRNSHolding(s) in Company
3rd Jan 20187:00 amRNSSigns 2nd agreement with US biopharma company
2nd Jan 20183:00 pmRNSTotal Voting Rights
21st Dec 20177:00 amRNSDirector/PDMR Shareholding
13th Dec 20177:01 amRNSExercise period extension existing Share Options
5th Dec 20177:00 amRNSEXERCISE OF WARRANTS AND DIRECTOR DEALING
15th Nov 20177:00 amRNSData at FNIH Biomarker Consortium Cancer Meeting
7th Nov 20177:00 amRNSAgreement with a major US biopharma company
6th Nov 201712:29 pmRNSNotification of major holdings
13th Oct 20177:00 amRNSPresents at the Diabetes Asia 2017 Conference
11th Oct 20177:00 amRNSPresents ALS signatures at NEALS
3rd Oct 20177:00 amRNSAnnounces grant of US patent for EpiSwitchT
28th Sep 20177:00 amRNSSuccessful in diagnosing and staging breast cancer
15th Sep 20177:00 amRNSDirectorate Update
30th Jun 20177:00 amRNSAppointment of Paul Stockdale as CFO
13th Jun 20177:00 amRNSInterim Results
13th Jun 20177:00 amRNSTargets Amyotrophic Lateral Sclerosis in Asia
31st May 20177:00 amRNSPublication highlights advantages of EpiSwitchT
31st May 20177:00 amRNSNotice of Interim Results
23rd May 20177:00 amRNSDevelopment Agreements with Top Pharma Companies

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.